6TCR
 
 | | Crystal structure of the omalizumab Fab Ser81Arg, Gln83Arg and Leu158Pro light chain mutant | | Descriptor: | 1,2-ETHANEDIOL, DI(HYDROXYETHYL)ETHER, Omalizumab Fab Ser81Arg, ... | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (1.45 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
6TCO
 | | Crystal structure of the omalizumab Fab Leu158Pro light chain mutant - crystal form I | | Descriptor: | 1,2-ETHANEDIOL, Omalizumab Fab Leu158Pro light chain mutant, SULFATE ION | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (1.8 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
6SV2
 | |
6SUZ
 | |
6TCM
 | | Crystal structure of the omalizumab Fab - crystal form I | | Descriptor: | (4S)-2-METHYL-2,4-PENTANEDIOL, GLYCEROL, Omalizumab Fab, ... | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (1.85 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
6TCS
 | | Crystal structure of the omalizumab scFv | | Descriptor: | DI(HYDROXYETHYL)ETHER, Omalizumab scFv | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-10-09 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
7FIG
 | | luteinizing hormone/choriogonadotropin receptor(S277I)-chorionic gonadotropin-Gs complex | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Camelid antibody VHH fragment Nb35, Choriogonadotropin subunit beta 3, ... | | Authors: | Duan, J, Xu, P, Cheng, X, Mao, C, Croll, T, He, X, Shi, J, Luan, X, Yin, W, You, E, Liu, Q, Zhang, S, Jiang, H, Zhang, Y, Jiang, Y, Xu, H.E. | | Deposit date: | 2021-07-31 | | Release date: | 2021-09-29 | | Last modified: | 2022-02-16 | | Method: | ELECTRON MICROSCOPY (3.9 Å) | | Cite: | Structures of full-length glycoprotein hormone receptor signalling complexes.
Nature, 598, 2021
|
|
7F5G
 | | The crystal structure of RBD-Nanobody complex, DL4 (SA4) | | Descriptor: | ACETATE ION, GLYCEROL, Nanobody DL4, ... | | Authors: | Li, T, Lai, Y, Zhou, Y, Tan, J, Li, D. | | Deposit date: | 2021-06-22 | | Release date: | 2022-05-25 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (1.75 Å) | | Cite: | Isolation, characterization, and structure-based engineering of a neutralizing nanobody against SARS-CoV-2.
Int.J.Biol.Macromol., 209, 2022
|
|
6TCQ
 | | Crystal structure of the omalizumab Fab Ser81Arg and Gln83Arg light chain mutant | | Descriptor: | GLYCEROL, Omalizumab Fab Ser81Arg and Gln83Arg light chain mutant | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (2.05 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
6TCN
 | | Crystal structure of the omalizumab Fab - crystal form II | | Descriptor: | 1,2-ETHANEDIOL, 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, DI(HYDROXYETHYL)ETHER, ... | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
8TEA
 | |
7DQ7
 | | Cryo-EM structure of Coxsackievirus B1 mature virion in complex with nAb 5F5 | | Descriptor: | 5F5 VH, 5F5 VL, Capsid protein VP4, ... | | Authors: | Li, S, Zhu, R, Xu, L, Cheng, T, Zheng, Q. | | Deposit date: | 2020-12-22 | | Release date: | 2021-05-05 | | Method: | ELECTRON MICROSCOPY (3.2 Å) | | Cite: | Cryo-EM structures reveal the molecular basis of receptor-initiated coxsackievirus uncoating.
Cell Host Microbe, 29, 2021
|
|
6ZLR
 | |
8YN6
 | | Cryo-EM structure of histamine H3 receptor in complex with imetit and Gi | | Descriptor: | 2-(1~{H}-imidazol-5-yl)ethyl carbamimidothioate, Antibody fragment scFv16, CHOLESTEROL, ... | | Authors: | Zhang, X, Liu, G, Li, X, Gong, W. | | Deposit date: | 2024-03-10 | | Release date: | 2024-10-09 | | Method: | ELECTRON MICROSCOPY (2.77 Å) | | Cite: | Structural basis of ligand recognition and activation of the histamine receptor family
Nat Commun, 15, 2024
|
|
1MVF
 | | MazE addiction antidote | | Descriptor: | PemI-like protein 1, immunoglobulin heavy chain variable region | | Authors: | Loris, R, Marianovsky, I, Lah, J, Laeremans, T, Engelberg-Kulka, H, Glaser, G, Muyldermans, S, Wyns, L. | | Deposit date: | 2002-09-25 | | Release date: | 2003-06-10 | | Last modified: | 2011-07-13 | | Method: | X-RAY DIFFRACTION (1.65 Å) | | Cite: | Crystal structure of the intrinsically flexible addiction antidote MazE.
J.Biol.Chem., 278, 2003
|
|
8U4Q
 | |
8U4T
 | |
8U4S
 | |
8U4R
 | |
2CK0
 | |
1BEV
 | | BOVINE ENTEROVIRUS VG-5-27 | | Descriptor: | BOVINE ENTEROVIRUS COAT PROTEINS VP1 TO VP4, MYRISTIC ACID, SULFATE ION | | Authors: | Smyth, M, Tate, J, Lyons, C, Hoey, E, Martin, S, Stuart, D. | | Deposit date: | 1996-04-03 | | Release date: | 1998-09-16 | | Last modified: | 2024-02-07 | | Method: | X-RAY DIFFRACTION (3 Å) | | Cite: | Implications for viral uncoating from the structure of bovine enterovirus.
Nat.Struct.Biol., 2, 1995
|
|
7KNA
 | | Localized reconstruction of the H1 A/Michigan/45/2015 ectodomain displayed at the surface of I53_dn5 nanoparticle | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Hemagglutinin,I53_dn5 | | Authors: | Acton, O.J, Park, Y.J, Veesler, D, Seattle Structural Genomics Center for Infectious Disease (SSGCID) | | Deposit date: | 2020-11-04 | | Release date: | 2021-03-31 | | Last modified: | 2024-05-01 | | Method: | ELECTRON MICROSCOPY (3.3 Å) | | Cite: | Quadrivalent influenza nanoparticle vaccines induce broad protection.
Nature, 592, 2021
|
|
8YNA
 | | Cryo-EM structure of histamine H4 receptor in complex with immepip and Gi | | Descriptor: | 4-(1H-imidazol-5-ylmethyl)piperidine, Antibody fragment scFv16, CHOLESTEROL, ... | | Authors: | Zhang, X, Liu, G, Li, X, Gong, W. | | Deposit date: | 2024-03-10 | | Release date: | 2024-10-09 | | Method: | ELECTRON MICROSCOPY (2.63 Å) | | Cite: | Structural basis of ligand recognition and activation of the histamine receptor family
Nat Commun, 15, 2024
|
|
7BU7
 | | Structure of human beta1 adrenergic receptor bound to BI-167107 and nanobody 6B9 | | Descriptor: | (2S)-2,3-dihydroxypropyl (7Z)-tetradec-7-enoate, 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID, 8-[(1R)-2-{[1,1-dimethyl-2-(2-methylphenyl)ethyl]amino}-1-hydroxyethyl]-5-hydroxy-2H-1,4-benzoxazin-3(4H)-one, ... | | Authors: | Xu, X, Kaindl, J, Clark, M, Hubner, H, Hirata, K, Sunahara, R, Gmeiner, P, Kobilka, B.K, Liu, X. | | Deposit date: | 2020-04-04 | | Release date: | 2020-12-02 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | Binding pathway determines norepinephrine selectivity for the human beta 1 AR over beta 2 AR.
Cell Res., 31, 2021
|
|
7BU6
 | | Structure of human beta1 adrenergic receptor bound to norepinephrine and nanobody 6B9 | | Descriptor: | (2S)-2,3-dihydroxypropyl octanoate, 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID, CHOLESTEROL, ... | | Authors: | Xu, X, Kaindl, J, Clark, M, Hubner, H, Hirata, K, Sunahara, R, Gmeiner, P, Kobilka, B.K, Liu, X. | | Deposit date: | 2020-04-04 | | Release date: | 2020-12-02 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Binding pathway determines norepinephrine selectivity for the human beta 1 AR over beta 2 AR.
Cell Res., 31, 2021
|
|
